Prevalence of HPV types in a cohort of Greeks with clinical indication of infection

BACKGROUND

Several types of human papilloma virus (HPV) have been associated with increased risk for epithelial malignancies. In light of a recently available vaccine that protects against persistent infection by certain HPV types (6, 11, 16, 18) and resulting neoplasias, the prevalence of HPV types was investigated in a cohort of people with a suspected viral infection.

PATIENTS AND METHODS

The studied material consisted of genital or oral scrapings obtained from 263 consecutively referred Greeks (aged 18-64 years) with a clinical indication of HPV infection. DNA samples isolated from scrapings were tested by PCR, using consensus primers for at least 50 HPV types. In cases of detected viral DNA sequence, HPV typing was performed by restriction analysis using 4 enzymes and confirmed by DNA sequencing.

RESULTS

215/263 (81.7%) of the samples were HPV-positive. HPV types associated with high risk for neoplasias were detected in 91/215 (423%), intermediate risk types in 64/215 (29.8%) and low-risk types in 60/215 (27.9%) of the positive samples. A total of 85/215 (39.5%) were positive for one of the vaccine-related types. Furthermore, types 16 and 18 comprised about the same proportion of the high-risk types detected in this study (35/91, 385%).

CONCLUSION

The observed high prevalence rate of high-risk types underlines the importance of testing individuals with an indication of a possible HPV infection. In addition, there is a need for prevention strategies, such as the annual Pap smear screening of women, as well as wider use of HPV molecular screening and vaccines targeted at common HPV types.

Immunological and molecular detection of human immunodeficiency virus in saliva, and comparison with blood testing

In order to test the detection feasibility of human immunodeficiency virus (HIV) in saliva, a three-method blind screening analysis was conducted. Sixty-eight individuals were studied, comprising 34 HIV carriers and 34 noncarriers (controls) of matched gender and age. An oral examination preceded saliva and blood sampling of studied individuals. All samples were tested blind for HIV by using two immunological methods [Oraquick-compatible enzyme-linked immunosorbent assay (ELISA) and a fluorescent immunoenzymatic method (ELFA)], confirmed by western blotting, and a simple molecular method (polymerase chain reaction amplification of a relatively constant viral DNA region), confirmed by DNA hydridization. Compared with the controls, about twice as many HIV carriers had oral health problems, including periodontal disease. ELFA resulted in 33/34 positives and 34/34 negatives in saliva, while it detected 34/34 positives and 34/34 negatives in blood. ELISA performed even better, with correct assignment of all positives and negatives in both saliva and blood. The PCR method, at three annealing temperatures, surprisingly detected all positive samples, while it gave no false-positive result. In conclusion, the detection of anti-HIV in saliva may achieve accuracy of 97.1-100%, comparable with that in blood. Furthermore, this study suggests that a highly accurate molecular method of HIV detection may be feasible, although the studied carriers had rather homogeneous characteristics.